The University of Kansas Heartland Institute for Clinical and Translational Research (HICTR) was established in 2007 in response to the national CTSA initiative. The vision ofthe HICTR is to Improve the health of Kansans by creating a novel and transformative translational research enterprise from bench to bedside to community. Particular strengths of our HICTR program are an entrepreneurial drug and device discovery and development program and a well-developed and highly accomplished community-based research program.
The specific aims of the HICTR are to: 1) create a new academic home with innovative training programs for clinical and translational investigators;2) provide an enhanced coordinated translational research infrastructure;and 3) actively engage the community in developing, testing, and disseminating research, by capitalizing on and expanding existing networks, to improve the health of all Kansans?especially those in rural, underserved and other target communities. The proposed infrastructure and educational programs ofthe HICTR will address the challenges facing clinical and translational investigators by enhancing and integrating existing resources for easier access, developing new innovative resources, and capitalizing on resources residing in research centers across the university-including our KINBRE and five COBRE grants~and our HICTR network institutions. In support of our aims, we have marshaled an impressive array of institutional, corporate, and community resources in planning, developing, and establishing the HICTR. The HICTR will provide new infrastructure and training and educational programs to support investigators'clinical and translational research?taking laboratory discoveries to first trials in humans (Tl research) and moving research through to studies on dissemination and implementation of research findings to practice (T2 research). With extraordinary institutional and community support, we already have made tremendous progress. Funding from the CTSA program will allow the University of Kansas'HICTR the opportunity to fully realize its potential not only for our region, but also to contribute to the national CTSA Consortium.

Public Health Relevance

The University of Kansas Heartland Institute for Clinical and Translational Research is an academic home for clinical and translational research, providing support to scientists and involving the community, so that discoveries and research findings will be brought more rapidly to the point of care, thus improving the health of all Kansans.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Training Award (TL1)
Project #
5TL1TR000120-04
Application #
8638996
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Program Officer
Merchant, Carol
Project Start
2011-06-01
Project End
2016-02-29
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
4
Fiscal Year
2014
Total Cost
$139,798
Indirect Cost
$8,856
Name
University of Kansas
Department
Neurology
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Morris, Jill K; Piccolo, Brian D; Shankar, Kartik et al. (2018) The serum metabolomics signature of type 2 diabetes is obscured in Alzheimer's disease. Am J Physiol Endocrinol Metab 314:E584-E596
Kopjar, Branko; Bohm, Parker E; Arnold, Joshua H et al. (2018) Outcomes of Surgical Decompression in Patients With Very Severe Degenerative Cervical Myelopathy. Spine (Phila Pa 1976) 43:1102-1109
Carrillo, Shane; Nazir, Niaman; Howser, Eric et al. (2017) Impact of the 2015 CMS Inpatient Psychiatric Facility Quality Reporting Rule on Tobacco Treatment. Nicotine Tob Res 19:976-982
Britt, Nicholas S; Potter, Emily M; Patel, Nimish et al. (2017) Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant Enterococcus faecium Bacteremia. Antimicrob Agents Chemother 61:
Koestler, Devin C; Usset, Joseph; Christensen, Brock C et al. (2017) DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio: An Epigenetic Tool to Explore Cancer Inflammation and Outcomes. Cancer Epidemiol Biomarkers Prev 26:328-338
Bohm, Parker E; Fehlings, Michael G; Kopjar, Branko et al. (2017) Psychometric properties of the 30-m walking test in patients with degenerative cervical myelopathy: results from two prospective multicenter cohort studies. Spine J 17:211-217
Whiles, Bristol B; Deis, Amanda S; Simpson, Steven Q (2017) Increased Time to Initial Antimicrobial Administration Is Associated With Progression to Septic Shock in Severe Sepsis Patients. Crit Care Med 45:623-629
Britt, Nicholas S; Patel, Nimish; Shireman, Theresa I et al. (2017) Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia. J Antimicrob Chemother 72:535-542
Fletcher, Amanda N; Molteni, Agostino; Ponnapureddy, Rakesh et al. (2017) The renin inhibitor aliskiren protects rat lungs from the histopathologic effects of fat embolism. J Trauma Acute Care Surg 82:338-344
Nwachokor, J; Tawfik, O; Danley, M et al. (2017) Quantitation of spatial and temporal variability of biomarkers for Barrett's Esophagus. Dis Esophagus 30:1-8

Showing the most recent 10 out of 75 publications